Tempus AI, Inc. (NASDAQ:TEM) Major Shareholder Sells $9,301,500.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) major shareholder Bradley A. Keywell sold 265,000 shares of the business’s stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $35.10, for a total value of $9,301,500.00. Following the sale, the insider now owns 15,218,365 shares in the company, valued at approximately $534,164,611.50. The trade was a 1.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Tempus AI Trading Up 1.2 %

NASDAQ:TEM opened at $35.15 on Friday. The stock’s 50 day moving average price is $46.03 and its 200 day moving average price is $47.18. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $79.49.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. NEA Management Company LLC acquired a new stake in shares of Tempus AI in the 2nd quarter valued at $160,048,000. Novo Holdings A S acquired a new stake in shares of Tempus AI in the second quarter worth about $142,605,000. ARK Investment Management LLC boosted its stake in shares of Tempus AI by 355.0% during the 3rd quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock worth $134,604,000 after acquiring an additional 1,855,459 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Tempus AI by 1,591.2% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after acquiring an additional 1,145,698 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA bought a new position in shares of Tempus AI in the 2nd quarter valued at approximately $28,246,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on TEM. Bank of America boosted their price target on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th. Needham & Company LLC restated a “buy” rating and issued a $56.00 target price on shares of Tempus AI in a report on Tuesday, January 14th. Guggenheim began coverage on Tempus AI in a report on Monday, December 9th. They set a “buy” rating and a $74.00 price target on the stock. Wolfe Research initiated coverage on Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Finally, Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and lifted their target price for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $56.36.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.